curriculum vitae€¦ · al-tahan am, al-jumah ma, bohlega sm, al-shammari sn, al-sharoqi ia, hosny...

1

CURRICULUM VITAE

A. PERSONAL EXPERIENCE:

1. PERSONAL INFORMATION

Name: Bassem I. Yamout

D.O.B: April 19th, 1961

Nationality: Lebanese

Department: Internal medicine, School of medicine, American University of

Beirut Medical Center, Beirut-Lebanon.

2. EDUCATIONAL BACKGROUND

1977-1980: BS-American University of Beirut, Beirut-Lebanon.

1979-1984: MD-American University of Beirut, Beirut-Lebanon

1983-1984: Internship _ American University of Beirut.

1984-1987: Neurology Residency _ University of Cincinnati Medical Center.

1987-1988: Neuromuscular fellowship Montreal Neurological Institute, McGill

University, Montreal-Canada.

3. ACADEMIC APPOINTMENTS

1988-1990: Assistant Professor of internal medicine at the American University

of Beirut.

1990-1998: Clinical Assistant Professor of Internal Medicine at the American

University of Beirut.

1998-2011: Clinical Associate Professor of Internal Medicine at

the American University of Beirut.

2011-Present: Clinical Professor of Neurology at the American University of

Beirut

2011-Present: Director, Multiple Sclerosis Center Clinical Research.

American University of Beirut Medical Center

4. BOARD CERTIFICATION

2

Certified by the American board of neurology and psychiatry: 1990

5. AWARDS/ HONORS

1- Elected Fellow of the American Academy of Neurology, 2011

2- Jeanne-Timins Fellowship Award, Montreal Neurological Institute, 1987.

3- Dean’s honor list A.U.B. 1978 and 1979.

B. PUBLICATIONS:

1. ARTICLES

1. Yamout B, Zeineddine M, Sawaya R and Khoury S. Safety and Efficacy of

Reduced Fingolimod Dosage Treatment. J Neuroim 2015 (In Press)

2. Yamout B, Alroughani R, Al-Jumaa M, Goueider R, Dahdaleh M, Inshasi J,

Hashem S, Alsharoqi I,Sahraian, M, Khoury S, Alkawi Z, Koussa S, Zakaria M, Al

Khaburi J, Alsaadi T, Bohlega S. Consensus Recommendations for the Diagnosis

and Treatment of Multiple Sclerosis:The Middle East North Africa Committee for

Treatment and Research in Multiple Sclerosis (MENACTRIMS). Current Medical

Research and Opinion 2015 (In Press)

3. Rahhal E, Hajjar H, Rajeh M, Abdelnoor AM and Yamout B. EBV and HHV-6A

DNA enhance IL-17 production in BALB/c mice and in HHV-6 infected cells from

multiple sclerosis patients. Viral Immunology 2015 (In Press)

4. Mouhieddine TH, Darwish H, Fawaz L, Yamout B, Tamim H. Risk factors for

Multiple Sclerosis and associations with anti-EBV antibody titers. Clinical

Immunology 2015 (In Press)

5. Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi I, AlTahan A,S

Bohlega, Daif A, Deleu D, Amous A, Inshasi J, Rieckmann P, Sahraian M,

Yamout B. Functional clinical outcomes in multiple sclerosis: Current status and

future prospects. Multiple Sclerosis and Related Disorders 2015; 4:192-201

6. Rizk M, El Khatib M, Yamout B, Hujeily E, Ayoub S, Ayoub C, Skaf G.

Spontaneous intracranial hypotension syndrome treated with fludrocortisone.

Anesthesia and Analgesia Case Reports 2015; 4:8-11

7. Alroughani R, Aref H, Bohlega S, Dahdaleh M, Feki I, Al Jumah M, Al Kawi M,

Koussa S, Sahraian M, Alsharoqi I, Yamout B. Natalizumab treatment for multiple

sclerosis: Middle East and North Africa: regional recommendations for patient

selection and monitoring. BMC Neurol. 2014; 14: 27

3

8. AlTahan A, Alsharoqi I, Bohlega S, Dahdaleh M, Daif A, Deleu D, Esmat K,

Giampaolo D, Freedman M, GwilT M, Hosny H, Inshasi J, Aljumah M, Khalifa A,

Pakdaman H, Szolics M, Yamout B, Sahraian M, M Zakaria. Characteristics of

multiple sclerosis in the Middle East with special reference to the applicability of

international guidelines to the region. International Journal of Neuroscience 2014;

124:635-641

9. Yamout B, El-Salem K, Gebeily S, Khoury S, Abu Zaid N, Hamoulila K, Al

Halabi MS, Al Uqla Z, Al Hamadani H, Hamoodi H, Al Omar A, Dahdaleh M.

Multiple sclerosis in the Levant: a regional consensus statement. International

Journal of Neuroscience 2014 124:377-82.

10. Al Jumah M, Alroughani R, Alsharoqi I, Bohlega S, Dahdaleh M, Deleu D, Esmat

K, Khalifa A, Sahraian M, Szólics M, AlTahan A, Yamout B, Rieckmann P, A

Daif. Future of management of multiple sclerosis in the Middle East: a consensus

view from specialists in ten countries. Multiple Sclerosis International 2013;

2013:1-6

11. Yamout B; Al-Zaghal Z; El-Dahouk I; Farhat S; Sibai A; Hamdan A. Mean

Contact Quotient Using Electroglottography in Patients With Multiple Sclerosis.

Journal of Voice 2013; 27: 506-51

12. Yamout B; Alroughani R., Al-Jumah M., Khoury S., Abouzeid N., Dahdaleh M.,

Alsharoqi I., Inshasi J Hashem S., Zakaria M., El Kallab K., Alsaadi T., Tawfeek

T., Bohlega S. Consensus guidelines for the diagnosis and treatment of multiple

sclerosis. Current Medical Research and Opinion 2013; 29: 611-621

13. Yamout B; Issa Z; Herlopian A; El Bejjani M; Khalifa A; Ghadieh A; Habib R.

Predictors of Quality of Life among Multiple Sclerosis Patients: A Comprehensive

Analysis. Euro J Neurol 2013; 5: 756-764

14. Abboud H, Labreuche J, Arauz A, Bryer A, Lavados P, Massaro A, Collazos

M, Steg P, Yamout B, Vicaut

E, Amarenco

P. Demographics, socio-economic

characteristics, and risk factor prevalence in patients with non-cardioembolic

ischaemic stroke in low- and middle-income countries: the OPTIC registry. Int J

Stroke 2013; 100:4-13

15. Hamdan AL, Farhat S, Saadeh R, El-Dahouk I, Yamout B. Voice-related quality of

life in patients with multiple sclerosis. Autoimmune Diseases 2012; 2012:1438

16. Al-Tahan AM, Al-Jumah MA, Bohlega SM, Al-Shammari SN, Al-Sharoqi IA,

Hosny HM, Yamout B. The importance of quality-of-life assessment in the

management of patients with multiple sclerosis. Recommendations from the

Middle East MS Advisory Group. Neurosciences 2011; 16:109-113

4

17. Yamout B, Heropian A, Issa Z, Habib R, Fawwaz A, Salame J, Wadih A, Awdeh

H, Muallem N, Raad R, Al-Kutoubi A. Response to letter on extracranial venous

stenosis in relapsing-remitting multiple sclerosis patients. Mult Scler 2011; 17:

643-645.

18. Deleu D, Al Jumah M, Al-Tahan A, Bohlega S, Dahdaleh M, Inshasi J, Khalifa A,

Szolics M, Yamout B, Alsharoqi I. Will new injection devices for interferon beta-

1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert

opinion in the Middle East. Int J Neurosci 2011; 121:171-175.

19. Yamout B, Heropian A, Issa Z, Habib R, Fawwaz A, Salame J, Wadih A, Awdeh

H, Muallem N, Raad R, Al-Kutoubi A. Extracranial venous stenosis is an

unlikely cause of Multiple Sclerosis. Mult Scler 2010; 16: 1341.

20. Yamout B, Hourani R, Salti H., Barada W, El-Hajj T, Koutobi A, Herlopian A,

Bazz E, Mahfouz R, Khalil-Hamdan R, Kreidyeh N, El-Sabban M, Bazarbachi A.

Bone marrow mesenchymal stem cell transplantation in patients with multiple

sclerosis: a pilot study. Journal of Neuroimmunology 2010; 227: 185–189.

21. Masroujeh R, Otrock Z, Yamout B, Jabbour M, Bazarbachi A. Myasthenia gravis

developing in a patient with CNS lymphoma. International Journal of Hematology

2010; 120: 522-524.

22. Yamout B, Itani S, Hamzeh D, Arabi A, Yaghi S. Prognostic factors of Multiple

Sclerosis in Lebanon. The International Journal of Neuroscience, 2010; 120(3);

206-10.

23. Yamout B, Itani S, Hourany R, Mehio-Sibai A, Yaghi S. The effect of war stress

on Multiple Sclerosis exacerbations and radiological disease activity. Journal of the

Neurological Sciences, 2010; 288: 42-44.

24. Yamout B, Dahdaleh M, Al-Jumah MA, Al-Shammri S, Al. Sharoqi I, Al-Tahan

AR, Bohlega S, Deleu D, Inshasi J, Khalifa A, Szólics M. Adherence to disease

modifying drugs in patients with multiple sclerosis: A consensus statement from

the Middle East/Near East MS Advisory Group. The International Journal of

Neuroscience, 2010; 120(4):273-9.

25. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen

P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ; CLARITY Study

Group(Yamout B is listed as an investigator and member of the CLARITY Study

Group). A placebo-controlled trial of oral cladribine for relapsing multiple

sclerosis. N Engl J Med. 2010,362(5):416-26.

5

26. Yamout B., Fuleihan N, Hajj T, Sibai A, Sabra O, Rifai H, Hamdan AL. Vocal

symptoms and acoustic changes in relation to the expanded disability status scale,

duration and stage of disease in patients with multiple sclerosis. Eur Arch

Otorhinolaryngol, 2009; 266: 1759-1765.

27. Yamout B, Usta J, Itani S, Yaghi S. Celiac disease, Behçet, and Idiopathic

Thrombocytopenic Purpura in siblings of a patient with Multiple Sclerosis.

Multiple Sclerosis, 2009; 15: 1368-71.

28. Hourani R, El-Hajj T, Barada W, Hourani M, Yamout B*. MR Imaging Findings

in Autosomal Recessive Hereditary Spastic Paraplegia. American Journal of

Neuroradiology, May 2009; 30: 936-40.

29. Bohlega S, Al-Shammri S, Al. Sharoqi I, Dahdaleh M, Gebeily S, Inshasi J,

Khalifa A, Pakdaman ., Szólics M, Yamout B*. Biosimilars: opinion of an expert

panel in the Middle East. Current Medical Research and Opinion, 2008; 24: 2897-

2903.

30. Yamout B, Barada W, Tohme RA, Mehio-Sibai A, Khalifeh R, El-Hajj T. Clinical

characteristics of Multiple Sclerosis in Lebanon. Journal of the Neurological

Sciences, 2008; 270: 88-93.

31. Sinno D, Darras B, Yamout B, Rebeiz J, Mikati M. A. Motor Variant of Chronic

Inflammatory Demyelinating Polyneuropathy in a child. Pediatric Neurology,

2008; 38: 426-429.

32. El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati M. A. Predictors of bone

density in ambulatory patients on antiepileptic drugs. Bone, 2008; 43: 149-55.

33. Yamout B. Extreme Circumstances, extraordinary measures. Good Clinical

Practice Journal, 2008; 15: 33-35.

34. Hourani R, Barada W, El Hajj T, Hourani M, Yamout B*. Posterior column

atrophy in autosomal recessive hereditary spastic paraplegia: MRI findings.

European Journal of Radiology, 2008; 65: 37-41.

35. Yamout B, El-Hajj T, Barada W, Uthman I. Successful treatment of refractory

Neurosjogren with Rituximab. Lupus, 2007; 16: 521-523.

36. Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, El-Hajj Fuleihan G.

Two randomized vitamin D trials in ambulatory patients on anticonvulsants:

Impact on bone (letter). Neurology, 2007; 68: 1958 - 1959.

6

37. Mikati M.A, Dib L, Yamout B, Sawaya R, Rahi AC and Fuleihan G. El-Hajj. Two

randomized vitamin D trials in ambulatory patients on anticonvulsants: Impact on

bone. Neurology, 2006; 67: 2005-2014.

38. Gus A. Baker, Ann Jacob, Joanne Gorry, Julie Doughty and Veronica Ellina, on

behalf of the SIGN Group (Yamout B.). Quality of life of people with epilepsy in

Iran, the gulf, and Near East. Epilepsia, 2005; 46 (1):132-140.

39. Kanj SS, Kanafani ZA, Khneisser I, Sawaya RA, Abdallah MS, Yamout B., Matar

GM. Human herpes virus 6 in patients with Bell’s palsy. J Appl Res 2003; 3:239-

241.

40. Christie S, Gobel H, Mateos V, Allen C, Vrijens F, Shivaprakash M, and the

Rizatriptan-ergotamine/Caffeine Preference Study Group (Yamout B.). Crossover

comparison of efficacy and preference for Rizatriptan 10 mg versus

Ergotamine/caffeine in migraine. Eur Neurol, 2003; 49:20-29.

41. Chehal A, Haidar JH, Jabbour R, Yamout B, Bazarbachi A. Obstructive sleep

apnea secondary to chronic lymphocytic leukemia. Ann Oncol, 2002; 13 (11):1833.

42. Farhat G, Yamout B, Mikati M.A, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect

of antiepileptic drugs on bone density in ambulatory patients. Neurology, 2002;

58:1348-1353.

43. Mansour A, Chamseddine A, Yamout B*, Solitary Metastasis to the Oculomotor

Nuclear complex. Annals of Ophthalmology, 2000; 32 (3):201-203.

44. Azar. S.T., Yamout B*. Prolactin secretion is increased in patients with multiple

sclerosis. Endocrine Research, 1999; 25: 207-14.

45. Nuwayhid I, Yamout B, Azar G. The effects of narghille smoking on pregnancy

outcome. The American Journal of Epidemiology, 1998; 148: 375-383.

46. Fayyad M, yamout B, Mroueh S. Alpha Interferon in the Treatment of Subacute

Sclerosing. Panencephalitis. Journal of Child Neurology, 1997; 12: 486-488.

47. Yamout B, Zaytoun G, Nuweihed I. The role of facial nerve conduction studies

and electromyography in predicting the outcome of Bell’s palsy. European Journal

of Neurology, 1997; 4: 1-4.

7

48. Deeb L, Yamout B, Shamseddine A, Shabb N, Uthman S. Meningeal

Carcinomatosis as the presenting manifestation of gastric adenocarcinoma.

American Journal of Gastroenterology, 1997; 92: 329-331.

49. Yamout B, Farhat W, Nuweihed I, Hushaymi I. Changes in migraine’s symptoms

from childhood to adolescence. European Neurology, 1996; 36:174-176.

50. Yamout B, Nassar N, Ghayyad E, Habbal A. Neurobrucellosis: Clinical

presentation, treatment and outcome in seven cases. Mediterranean Journal of

infectious and Parasitic Diseases, 1996; 11: 111-115.

51. Yamout B, Kyriakides T, Tamim W, Drousiotov A. Myalgia, neuromyopathy and

internalized capillaries. A steroid-responsisve syndrome. Acta Neurologica

Scandinavica, 1995; 91: 294-296.

52. Khalil A, Yamout B, Tabbal S, Salem Z, Mroueh A. Case report and review of

literature: leptomeningeal relapse in epithelial ovarian cancer. Gynecologic

Oncology, 1994; 54: 227-231.

53. Yamout B, Tayyim A, Farhat W. Meralgia paresthetica as a complication of

laparoscopic cholecystectomy. Clinical neurology and neurosurgery, 1994; 96:

143-144.

54. Francis GS, Bonni A, Shen Hechtman P, Yamout B, Carpenter S, Karpati G,

Chang PL. Metachromatic leukodystrophy: multiple nonfunctional and

pseudodeficiency alleles in a pedigree: problem with diagnosis and counseling.

Ann Neurol, 1993; 34: 212-218.

* Senior author

2. PRESENTATIONS AT MEETING

a. Oral Presentations:

1. Yamout B, Nassar N, Ghayyad E, Habbal A. Neurobrucellosis: Clinical

presentation, treatment and outcome in seven cases. Presented at the American

Academy of Neurology Meeting, San Francisco, 1996.

2. Fayyad M, Yamout B, Mroueh S. Alpha Interferon in the Treatment of Subacute

Sclerosing Panencephalitis. Presented at the International Workshop in Ankara,

1995.

8

3. Noureddine B, Yamout B. Visual field changes in multiple sclerosis. Presented at

the third International Meeting of the Pan-Arab Council of Ophtamology in

Marakesh, Morroco, 1995.

4. Yamout B, Carpenter S, Karpati G. A peculiar form of steroid resistant chronic

inflammatory myopathy. Neurology. Presented at the American Academy of

Neurology Meeting in Cincinati, 1988.

b. Posters:

1. Alroughani R, Aljumah MA, Aref H, Bohlega S, Al Sherooqi IA, Dahdaleh M, Feki

I, Al-Kawi MZ, Koussa S, Sahraian MA, Yamout B. Natalizumab Treatment for

Multiple Sclerosis: MENA (Middle East and North Africa) regional

recommendations for patient selection and monitoring. Presented at the 23rd

European Neurological Society Meeting, June 2013; Barcelona-Spain

2. Yamout B, Issa Z, Herlopian A, El-Bajjani M, Khalifa A, Habib RH. Predictors of

Quality of Life in Patients with Multiple Sclerosis: A Comprehensive Analysis.

Presentated at the American Academy of Neurology 63rd

Annual Meeting, April

2011; Honolulu-USA

3. Yamout B, Herlopian A, Issa Z, Habib R, Fawaz A, Salame J, Wadih A, Awdeh H,

Muallem N, Raad R, Al-Kutoubi A. Chronic cerebrospinal venous insufficiency is an

unlikely cause of multiple sclerosis. Presented at the 26th

Congress of the European

Committee for the Treatment and Research in Multiple Sclerosis, Gothenburg-

Sweden 2010. Nominated for best poster prize at the ECTRIMS 2010

4. Yamout B., Hourani R., Salti H., Barada W., El-Hajj T., Skaff G., Koutobi A., Bazz

E., Mahfouz R., Khalil-Hamdan R., Kreidyeh N., El-Sabban M., Bazarbachi A. Bone

marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a

pilot study. Presented at the 25th

congress of the European Committee for Treatment

and Research in Multiple Sclerosis, Düsseldorf, Germany 2009.

5. Clinical Characteristics of multiple sclerosis in Lebanon. Presented at the 23rd

congress of the European Committee for Treatment and Research in Multiple

Sclerosis, Prague, Czech Republic 2007 .

6. B. Yamout, G. Skaff, M. Khalife, W. Barada, R. Hourani, E. Bazz, R. Mahfouz, M.

Sabban, H. Khoury and A. Bazarbachi. Bone Marrow Mesenchymal Stem Cell

Transplantation in Patients with Multiple Sclerosis and Severe Disability: a Pilot

Study. Presented at the European Charcot Foundation Symposium, “Mending the

Brain”. Stem cells and repair in Multiple Sclerosis”, November 2006. Taormina

Sicily.

9

7. Yamout B, Azar S, Haidar S. Serum prolactin level during acute exacerbations of

multiple sclerosis. Presented at the Endocrine Society meeting in Anaheim _

California, June 1994.88

8. Karpati G, Carpenter S, Shoubridge E, Arnold D, Yamout B, Waddell R.

Mitochondrial myopathy in primary biliary cirrhosis: an antibody-mediated

cytopathy. Neurology, 38 (supl 1): 114, 1988.

9. Yamout B, Iannaccone S, Hug G. Infantile peripheral neuropathy associated with

carnitine deficiency. Neurology, 36 (supl 1): 81, 1986.

3. CURRENT RESEARCH

1. Rituximab therapy in multiple sclerosis patients failing on standard interferon

treatment. B. Yamout, A. Herlopian, M. Bajani

2. Human Herpes viridae infections and immune-related markers in the evolution of

multiple sclerosis. E. Rahhal, A. Abdelnoor, B. Yamout.

4. PAST INTERNATIONAL MULTICENTER TRIALS:

1. CLARITY trial: A Phase Ш, randomized, double-blind, three-arm, placebo-

controlled, multi-center study to evaluate the safety and efficacy of oral

Cladribine in subjects with relapsing-remitting multiple sclerosis (RRMS)

2. CLARITY Extension trial: A Phase Шb, Double-Blind, Placebo-Controlled,

Multicenter, Parallel Group, Extension Trial to Evaluate the safety and

Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting

Multiple Sclerosis Who Have Completed Trial 25643 .

3. ATAMS trial: A four-arm randomized, double-blind, placebo-controlled,

multicenter Phase II study to evaluate the safety, tolerability and efficacy as

assessed by frequent MRI measures of three doses of Atacicept monotherapy

in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks

treatment course.

4. REFLEXION trial: Double-blind extension of the study 27025 (REFLEX) to

obtain long-term follow-up data in patients with clinically definite MS and

patients with a first demyelinating event at high risk of converting to MS,

treated with Rebif New Formulation

10

5. ATAMS Extension trial: An open label, multicenter phase II extension of

study 28063 (ATAMS) to obtain long term follow up data in subjects with

relapsing multiple sclerosis treated with Atacicept for up to 5 years .

6. ATONS trial: A two arm, randomized, double blind, placebo-controlled,

multicenter phase П study to evaluate safety and tolerability and to explore

the neuroprotective effect of Atacicept as assessed by Optical Coherence

Tomography (OCT) in subjects with Optic Neuritis (ON) as Clinically

Isolated Syndrome (CIS) over a 36 weeks treatment course.

7. REFLEX trial:A Phase III, randomized, double-blind, placebo-controlled,

multicenter clinical trial of Rebif® New Formulation (44 mcg tiw and 44

mcg ow) in subjects at high risk of converting to Multiple Sclerosis

8. ORACLE trial: A Phase III, randomized, double-blind, placebo-controlled,

multicenter clinical trial of oral cladribine in subjects with a first clinical event

at high risk of converting to MS (ORACLE MS).

5. INVITED PRESENTATIONS:

A. Local conferences:

April, 2015: Multiple sclerosis treatment guidelines

Lebanese Pharmacists Symposium

Beirut-Lebanon

November, 2014: Teriflunomide: A new approach to disease management in MS

The 6th

International Congress of the Lebanese Society of

Neurology

Beirut- Lebanon

March, 2014: Multiple sclerosis and pregnancy

Lebanese Society of Neurology Meeting

Dbayeh, Lebanon

October, 2012: Is it multiple sclerosis?

Lebanese Society of Family Medicine Annual conference

Beirut, Lebanon

11

July, 2011: New scope in multiple sclerosis

Novartis MS symposium

Saida, Lebanon

July, 2011: New perspectives in multiple sclerosis

Novartis MS symposium

Beirut, Lebanon

March, 2010: Stem cells, an evolving therapy in multiple sclerosis

Sixth Annual Congress of the Lebanese Order of Physicians

Tripoli, Lebanon

March, 2010: Pregnancy in multiple sclerosis

Sixth Annual Congress of the Lebanese Order of Physicians

Tripoli, Lebanon

February, 2010: Oral therapies in multiple sclerosis

Merck-Serono annual symposium on multiple sclerosis

Mount Lebanon, Lebanon

March, 2010: Management of pain in diabetic neuropathy

Lebanese ministry of health meeting

Beirut, Lebanon

October, 2009: Painful diabetic neuropathy

Lilly Symposium


July, 2009: Management of painful diabetic polyneuropathy

Lilly Symposium

Beirut, Lebanon

March, 2009: Stem cell therapy in multiple sclerosis. A pilot trial.

The 11th

Medical Seminar on Actualities in Neurology.

Notre Dame Du Liban Hospital.

March, 2008: Preventive stroke therapy

Lebanese Society of Neurosurgery annual meeting

Beirut, Lebanon.

March, 2008: Update on medical therapy of stroke

AUB Department of Family Medicine town meeting.

Beirut, Lebanon.

12

.

May, 2007: Management of Insomnia.

Bekaa Sanofi-Aventis symposium on sleep.

Chtaura, Lebanon.

September, 2006: Medical therapy of stroke.

Bekaa Sanofi-Aventis symposium on stroke.

Chtaura, Lebanon.

May, 2006: Management of Insomnia

Beirut Sanofi-Aventis symposium on sleep.

Beirut, Lebanon.

December, 2005: Role of neutralizing antibodies in interferon-treated MS

patients.

Serono symposium on early treatment in multiple

Sclerosis.

Beirut- Lebanon.

.

B. Regional conferences:

April, 2015: Safety and efficacy of Natalizumab

Iraqi Expert Meeting

Amman-Jordan

April, 2015: Natalizumab real world evidence: The Lebanese Cohort


Amman-Jordan

April, 2015: MENACTRIMS guidelines for treatment of multiple clerosis


Amman-Jordan

13

February, 2015: Oral DMTs: Spotlight on Teriflunomide

Treatment Paradigm in Evolving MS Landscape: Genpharm

Symposium

Dubai-UAE

February, 2015: Consensus recommendations for the treatment of MS

The 9th

Annual Egyptian Symposium on Epilepsy and Multiple

Sclerosis

Istanbul-Turkey

November, 2014: Current Approach to MS treatment

The 9th

GCC Neurology Conference

Muscat-Oman

November, 2014: Alemtuzumab experience in the Middle East

Genzyme Advisory Board Meeting

Muscat-Oman

October, 2014: New approach in MS therapy

The 11th

International Congress on MS in Iran

Genzyme Symposium

Tehran-Iran

October, 2014: Consensus recommendations for diagnosis and treatment of MS;

The MENACTRIMS Guidelines

First MENACTRIMS Congress

Dubai-UAE

October, 2014: Patient centric outcomes

Merck-Serono symposium

First MENACTRIMS C

Dubai-UAE

September, 2014: Time for change: Advancing our understanding of MS

Le 20eme Congres National De Neurologie

Novartis Symposium

Hammamat-Tunis

September, 2014: MENACTRIMS consensus guidelines for treatment of MS

Biologix Advisory Board Meeting

Dead Sea, Jordan

September, 2014: Personalizing treatment choices in MS

14

Jordan Neurological Society Meeting

Biologix Symposium

Dead Sea, Jordan

June, 2014: A new approach for treatment of relapsing MS

21th Congress of Neurology and Electrophysiology of Iran.

Tehran, Iran

June, 2014: Real world evidence: Effect of switching to fingolimod on

effectiveness, patient related outcomes, and adherence.

STEP Dubai Medical Summit

Dubai, UAE

April, 2014: The case for injectable vs oral therapies in MS

UAE Neurology Society Symposium: Changing MS landscape. A

debate for best patient’s outcome

Dubai, UAE

April, 2014: Diagnosing MS: The Middle East Guidelines

UAE Neurology Society Symposium: Changing MS landscape. A

debate for best patient’s outcome

Dubai, UAE

February, 2014: The Levant Experience with Fingolimod

UAE MS Forum

Dubai- UAE

February, 2014: The case for teriflunomide as first line therapy in MS

UAE MS Forum

Dubai- UAE

February, 2014: Multiple Sclerosis and Stress

The First Challenges in Clinical Neurology Congress

Kerman-Iran

November, 2013: Transition to new outcome measures in MS

The 8th

Middle East Merck Serono Multiple Sclerosis Advisory

Board Meeting

Istanbul-Turkey

November, 2013: Multiple Sclerosis and Stress

The 5th International Congress of the Lebanese Society of

Neurology

Beirut- Lebanon

November, 2013: Aubagio (Teriflunomide): A new approach to disease

15

Management

Genpharm-Genzyme Symposium

The 5th International Congress of the Lebanese Society of

Neurology

Beirut- Lebanon

May, 2013: Future Therapies in Multiple Sclerosis

The First Multiple Sclerosis Update Middle East Forum 2013-UAE

Abu Dhabi- UAE

May, 2013: Current Treatment of Multiple Sclerosis

The First Multiple Sclerosis Update Middle East Forum 2013-UAE

Abu Dhabi- UAE

April, 2013: Fingolimod Update from the American Academy of Neurology 2013

Transforming MS Treatment -Novartis Symposium

The First Kuwait North American Neurology Conference

Kuwait City- Kuwait

April, 2013: Health Economics in Multiple Sclerosis

The Iraqi National Committee Symposium

Sponsored by Novartis

Beirut- Lebanon

April, 2013: Two Years of Oral Therapy Experience in the Middle East



Beirut- Lebanon

April, 2013: Future Oral Therapies in Multiple Sclerosis



Beirut- Lebanon

April, 2013: Guidelines for management of multiple sclerosis



Beirut- Lebanon

February, 2013: Diagnosis and management of multiple sclerosis:

Practice Guidelines

The 13th

Congress of the Pan Arab Union of Neurological

Societies

Sharm El Sheikh- Egypt

February, 2013: Treatment of multiple sclerosis

16

Iraqi physicians training program at AUBMC

Beirut- Lebanon

January, 2013: Updated guidelines for multiple sclerosis therapy

The 7th

Educational Egyptian Epilepsy Association Symposium and

Multiple Sclerosis Update

Beirut- Lebanon

January, 2013: New oral therapies in multiple sclerosis

The 7th

Educational Egyptian Epilepsy Association Symposium and

Multiple Sclerosis Update

Beirut- Lebanon

December, 2012: Epidemiology of multiple sclerosis in Lebanon

MS in the 21st Century: The Seventh Intercontinental Multiple

Sclerosis Advisory Board Meeting

Dubai-UAE

November, 2012: Cerebrospinal Venous Insufficiency and MS

The 5th

International Congress of the Jordanian Society of

Neurology

Amman-Jordan

September, 2012: Stem Cells in MS

The Salim El-Hoss Bioethics and Professionalism Program

3rd

regional conference.

Stem Cell Research: Current Controversies

Beirut-Lebanon

June, 2012: Unmet needs in MS treatment

United Arab Emirates MS Advisory Board Meeting

Dubai-UAE

June, 2012: New Oral Therapies in MS

United Arab Emirates MS Advisory Board Meeting

Dubai-UAE

June, 2012: New Oral Therapies in MS

Egyptian MS Society Annual Meeting

Alexandria-Egypt

June, 2012: Multiple sclerosis in Lebanon

Multiple Sclerosis and Molecular Aspects in the Arab World

Arab Gulf University

Manama-Bahrain

17

June, 2012: Fingolimod: Clinical Experience in the Middle East as first line therapy

Middle East Perspectives in Neuroscience

Kuala Lumpur-Malaysia

May, 2012: Symptoms and diagnosis of MS

Kuwaiti Multiple Sclerosis Society Annual Meeting

Kuwait City-Kuwait

May, 2012 : Unmet needs in MS therapy

Novartis Regional MS Symposium

Beirut-Lebanon

May, 2012 : Fingolimod in MS therapy

Novartis Regional MS Symposium

Beirut-Lebanon

May, 2012 : New oral therapies in multiple sclerosis

The Second AUBMC Multiple Sclerosis Center Symposium

Beirut-Lebanon

May, 2012 : American University of Beirut Medical Center multiple sclerosis

practice guidelines

The Second AUBMC Multiple Sclerosis Center Symposium

Beirut-Lebanon

March, 2012 : Unmet needs in current multiple sclerosis therapy

Middle East Advisory Board meeting

Dubai-UAE

September, 2011 : Unmet needs in multiple sclerosis

Novartis Symposium

Broumana-Lebanon

September, 2011 : Fingolimod indications in clinical practice

Novartis Symposium

Broumana-Lebanon

July, 2011 : Innovative approach in treatment of Multiple Sclerosis

Iraqi neurology society meeting

Novartis symposium

Erbil-Iraq

March, 2011: Early Treatment and cognitive functioning in MS: Current evidence


Bayer symposium

18

Erbil-Iraq

March, 2011: Treating MS today: Balancing the therapeutic risk-benefit ratio


Bayer symposium

Erbil-Iraq

January, 2011: The theory of CCSVI in Multiple Sclerosis.

The Annual Multiple Sclerosis and Epilepsy Update Symposium

Cairo- Egypt

January, 2011: Stem cell in Multiple sclerosis.

The Annual Multiple Sclerosis and Epilepsy Update Symposium

Cairo- Egypt

January, 2011: Chronic cerebrospinal venous insufficiency in multiple sclerosis

King Faysal hospital - Neurology Grand Round

Riyadh- Saudi Arabia

November, 2010: Antiplatelets in Preventive Stroke Therapy

Sanofi-Aventis symposium on stroke and epilepsy

Istanbul-Turkey

September, 2010: Extracranial venous stenosis is an unlikely cause of multiple

Sclerosis

11th

Neuromediterranean Congress

Beirut-Lebanon

May, 2010: Oral Therapies in Multiple Sclerosis

12th

Congress of the Pan Arab Union of Neurological Societies

Damascus-Syria

April, 2010: Stem cell therapy in multiple sclerosis

43d Middle East Medical Assembly annual meeting

Beirut, Lebanon

April, 2010 : Multiple sclerosis diagnosis

Syrian society of neurology annual meeting

Damascus, Syria

February, 2010 : Treatment adherence to in multiple sclerosis

The Middle East Advisory Board on Multiple Sclerosis annual

meeting


19

October, 2009 : Oral therapies in multiple sclerosis

The Sixth Iranian International Congress on Multiple Sclerosis

Tabriz, Iran

February, 2009: Secondary stroke prevention: an update

Jordanian neurology society symposium on stroke and epilepsy

Dead Sea- Jordan.

November, 2008: Update on Multiple Sclerosis

International Congress on Multiple Sclerosis of Iran.

Tehran- Iran.

December, 2007: Update on medical therapy of stoke

Jordanian neurology society symposium on stroke and

epilepsy

Dead Sea- Jordan.

November, 2005: Early vs. delayed treatment in multiple sclerosis

Pan-Gulf neurology meeting.

Manama, Bahrain.

.

February, 2005: Preventive stroke therapy

The Iraqi neurology society annual conference.

Cairo- Egypt.

.

January, 2005: Multiple sclerosis and women.

Symposium on neurological diseases in women.

Kuwait city- Kuwait.

May, 2003: Early treatment of multiple sclerosis

Tenth international Iranian congress on neurology

Tehran- Iran.

.

May, 2002: a. Etiology and pathogenesis of multiple sclerosis.

b. Progression of disability in multiple sclerosis: mechanism,

clinical and MRI parameters.

Kuwaiti MS forum.

20

Kuwait city- Kuwait

April, 2000: Early Axonal Loss in Multiple Sclerosis: A New Disease Concept

The 8th

. Congress of the Pan Arab Union of Neurological Societies

Beirut-Lebanon:

.

C. International conferences:

March, 2015: Natalizumab efficacy and safety: Growing evidence from real life

Expect more in MS: Genzyme Symposium

Rome-Italy

December, 2014: Personalizing treatment choices in MS

Biologix Symposium

Paris-France

May, 2014: Patients related outcomes in MS

Serono Symposia International 2014 Annual Conference

Dubai-UAE

April, 2014: New directions and emerging therapies in MS

Second Multiple Sclerosis and Parkinson's Disease Workshop

Malaysian Society of Neurosciences

Kuala Lumpur, Malaysia

April, 2014: Brain volume loss in MS and its correlation to clinical outcomes

Second Multiple Sclerosis and Parkinson's Disease Workshop

Malaysian Society of Neurosciences

Kuala Lumpur, Malaysia

November, 2013: Can Stress Exacerbate MS?

3d International Congress of Neurology and epidemiology

Abu Dhabi-UAE

November, 2013: Practice Guidelines for the Management of Multiple Sclerosis

Merck-Serono Symposium


Abu Dhabi-UAE

November, 2013: Multiple Sclerosis: The Importance of Treatment Adherence

Merck-Serono Symposium


Abu Dhabi-UAE

June, 2012: Summary of fingolimod efficacy data

21

MS STEP Meeting


June, 2012: Fingolimod safety data and risk management

MS STEP Meeting


November, 2011: Multiple Sclerosis and Chronic Cerebrospinal Venous

Insufficiency.

XXth World Congress of Neurology

Marrakesh-Morocco

March, 2011: Epidemiology and clinical characteristics of MS in the Middle

East.

Eighth Regional MS Forum

Seville-Spain

May, 2010: Bone Marrow Mesenchymal Stem Cell Transplantation in Patients

With Multiple Sclerosis: A Pilot Study

Annual World Congress of Immunodiseases and Therapy 2010

(WCIT- 2010)

Beijing-China

May, 2010: Stem cells in multiple sclerosis

5th EEMCPDM meeting (Eastern European and Mediterranean

Cerebral Palsy and Developmental Medicine)

Beirut-Lebanon

October, 2007: Managing Clinical Trials Under War Conditions. The 2006

Lebanese-Israeli war experience.

2nd

Annual European Clinical Research Conference.

Madrid, Spain.

February, 2004: Neutralizing antibodies in INFB- treated multiple sclerosis

patients.

Serono regional meeting on treatment of multiple sclerosis.

Gstaad- Switzerland

October, 2002: Etiology and pathogenesis of multiple sclerosis: new concepts.

Serono regional meeting on multiple sclerosis.

Nairobi- Kenya.

22

5. EDITORIAL BOARDS:

Member, editorial board of Multiple Sclerosis and Related Disorders

Member, editorial board of Journal of Multiple Sclerosis

Member, editorial board of Annals of Autoimmunity and Research

Chief Editor, MS Today: newsletter on MS.

Member, review board of: Journal of Pediatric Neurology.

C. SERVICE:

1. PROFESSIONAL PRACTICE AND COMMUNITY:

President, MENACTRIMS

Head, Multiple Sclerosis Clinic and Research Center (2008-Present).

President of the National Multiple Sclerosis Society of Lebanon.

2. SERVICE TO THE PROFESSION:

Member of the Regional Advisory Board for Multiple Sclerosis in the

Middle East (sponsored my Merck-Serono Pharmaceuticals): 2007-

Present.

Member of the Intercontinental Advisory Board for Multiple Sclerosis

(sponsored by Merck-Serono Pharmaceuticals): 2009-Present.

Member of the Multiple Sclerosis Board for Asia-Pacific, Middle East &

Africa (sponsored by Novartis): 2010-Present.

Member of the King Faisal Foundation selection committee for the King

Faisal International Prize in Medicine: 2010-2011

Member of the Parliamentary national health committee: 2000-2005.

curriculum vitae€¦ · al-tahan am, al-jumah ma, bohlega sm, al-shammari sn, al-sharoqi ia, hosny...

Documents